Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
AstraZeneca
Moodys
Colorcon

Last Updated: January 28, 2023

Investigational Drug Information for Navitoclax


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Navitoclax?

Navitoclax is an investigational drug.

There have been 27 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2020.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, Lymphoid, and Leukemia. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.

There are five hundred and sixty-three US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Navitoclax
TitleSponsorPhase
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsAbbViePhase 1
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsJacqueline Garcia, MDPhase 1
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic SyndromeThomas Jefferson UniversityPhase 1/Phase 2

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Navitoclax See Plans and Pricing Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) See Plans and Pricing
Navitoclax See Plans and Pricing Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) See Plans and Pricing
Navitoclax See Plans and Pricing Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) See Plans and Pricing
Navitoclax See Plans and Pricing Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Navitoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Navitoclax Australia AU2012322660 2031-10-11 See Plans and Pricing
Navitoclax Australia AU2017228527 2031-10-11 See Plans and Pricing
Navitoclax Canada CA2851788 2031-10-11 See Plans and Pricing
Navitoclax Canada CA3173988 2031-10-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
AstraZeneca
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.